Treating the individual hypertensive patient: considerations on dose, sequential monotherapy and drug combinations. 1990

H R Brunner, and J Ménard, and B Waeber, and M Burnier, and J Biollaz, and J Nussberger, and M Bellet
Cardiovascular Research Group, University Hospital, Lausanne, Switzerland.

For the general practitioner to be able to prescribe optimal therapy to his individual hypertensive patients, he needs accurate information on the therapeutic agents he is going to administer and practical treatment strategies. The information on drugs and drug combinations has to be applicable to the treatment of individual patients and not just patient study groups. A basic requirement is knowledge of the dose-response relationship for each compound in order to choose the optimal therapeutic dose. Contrary to general assumption, this key information is difficult to obtain and often not available to the physician for many years after marketing of a drug. As a consequence, excessive doses are often used. Furthermore, the physician needs comparative data on the various antihypertensive drugs that are applicable to the treatment of individual patients. In order to minimize potential side effects due to unnecessary combinations of compounds, the strategy of sequential monotherapy is proposed, with the goal of treating as many patients as possible with monotherapy at optimal doses. More drug trials of a crossover design and more individualized analyses of the results are badly needed to provide the physician with information that he can use in his daily practice. In this time of continuous intensive development of new antihypertensive agents, much could be gained in enhanced efficacy and reduced incidence of side effects by taking a closer look at the drugs already available and using them more appropriately in individual patients.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004338 Drug Combinations Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture. Drug Combination,Combination, Drug,Combinations, Drug
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000959 Antihypertensive Agents Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. Anti-Hypertensive,Anti-Hypertensive Agent,Anti-Hypertensive Drug,Antihypertensive,Antihypertensive Agent,Antihypertensive Drug,Anti-Hypertensive Agents,Anti-Hypertensive Drugs,Anti-Hypertensives,Antihypertensive Drugs,Antihypertensives,Agent, Anti-Hypertensive,Agent, Antihypertensive,Agents, Anti-Hypertensive,Agents, Antihypertensive,Anti Hypertensive,Anti Hypertensive Agent,Anti Hypertensive Agents,Anti Hypertensive Drug,Anti Hypertensive Drugs,Anti Hypertensives,Drug, Anti-Hypertensive,Drug, Antihypertensive,Drugs, Anti-Hypertensive,Drugs, Antihypertensive

Related Publications

H R Brunner, and J Ménard, and B Waeber, and M Burnier, and J Biollaz, and J Nussberger, and M Bellet
April 1991, The American journal of medicine,
H R Brunner, and J Ménard, and B Waeber, and M Burnier, and J Biollaz, and J Nussberger, and M Bellet
October 2012, Journal of young pharmacists : JYP,
H R Brunner, and J Ménard, and B Waeber, and M Burnier, and J Biollaz, and J Nussberger, and M Bellet
June 1988, The Journal of family practice,
H R Brunner, and J Ménard, and B Waeber, and M Burnier, and J Biollaz, and J Nussberger, and M Bellet
January 1992, Drugs,
H R Brunner, and J Ménard, and B Waeber, and M Burnier, and J Biollaz, and J Nussberger, and M Bellet
May 1978, The American journal of nursing,
H R Brunner, and J Ménard, and B Waeber, and M Burnier, and J Biollaz, and J Nussberger, and M Bellet
March 1983, Dental student,
H R Brunner, and J Ménard, and B Waeber, and M Burnier, and J Biollaz, and J Nussberger, and M Bellet
October 2014, CNS spectrums,
H R Brunner, and J Ménard, and B Waeber, and M Burnier, and J Biollaz, and J Nussberger, and M Bellet
May 2016, The Cochrane database of systematic reviews,
H R Brunner, and J Ménard, and B Waeber, and M Burnier, and J Biollaz, and J Nussberger, and M Bellet
May 2000, Journal of evaluation in clinical practice,
H R Brunner, and J Ménard, and B Waeber, and M Burnier, and J Biollaz, and J Nussberger, and M Bellet
September 1990, Journal of the National Cancer Institute,
Copied contents to your clipboard!